WHAT IS CLAIMED IS:

1. Use of a monoclonal anti-beta7 antibody in the manufacture of a medicament for treating a gastrointestinal inflammatory disorder, wherein the anti-beta7 antibody is to be administered subcutaneously at a flat dose, wherein the anti-beta7 antibody comprises three heavy chain hypervariable region (HVR-H1-H3) sequences and three light chain hypervariable region (HVR-L1-L3) sequences, wherein:

(i) HVR-L1 comprises SEQ ID NO:9;
(ii) HVR-L2 comprises SEQ ID NO:2;
(iii) HVR-L3 comprises SEQ ID NO:3;
(iv) HVR-H1 comprises SEQ ID NO:4;
(v) HVR-H2 comprises SEQ ID NO:5; and
(vi) HVR-H3 comprises SEQ ID NO: 19.

2. The use of claim 1, wherein the anti-beta7 antibody is to be administered at a flat dose between about 50 mg and about 450 mg, wherein optionally the flat dose is selected from the group consisting of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 300 mg, about 350 mg, about 400 mg, about 420 mg, and about 450 mg, wherein optionally the anti-beta7 antibody is to be administered once every week, or once or every two weeks, or once every four weeks, or once every six weeks, or once every eight weeks, and wherein optionally the anti-beta7 antibody is to be administered for a period of two months, or three months, or six months, or 12 months, or 18 months, or 24 months, or for the lifetime of the patient.

3. The use of claim 1, wherein the patient is a human.

4. The use of claim 1, wherein the gastrointestinal inflammatory disorder is an inflammatory bowel disease, and wherein optionally the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

5. The use of claim 1, wherein the anti-beta7 antibody is selected from a chimeric antibody, a human antibody, and a humanized antibody.

6. The use of claim 5, wherein the anti-beta7 antibody is a humanized antibody.

7. The use of claim 1, wherein the anti-beta7 antibody is to be administered at a flat dose of about 100 mg or about 300 mg every four weeks, wherein the patient suffers from ulcerative colitis, and wherein the patient experiences mucosal healing or a reduced rate of flare over time.

8. Use of a monoclonal anti-beta7 antibody in the manufacture of a medicament for treating a gastrointestinal inflammatory disorder, wherein the anti-beta7 antibody is to be administered a first loading dose and at least one subsequent maintenance dose, wherein each of the loading dose and the at least one maintenance dose is to be administered subcutaneously at a flat dose, wherein the anti-beta7 antibody comprises three heavy chain hypervariable region (HVR-H1-H3) sequences and three light chain hypervariable region (HVR-L1-L3) sequences, wherein:

(i) HVR-L1 comprises SEQ ID NO:9;
(ii) HVR-L2 comprises SEQ ID NO:2;
(iii) HVR-L3 comprises SEQ ID NO:3;

(iv) HVR-H1 comprises SEQ ID NO:4;
(v) HVR-H2 comprises SEQ ID NO:5; and
(vi) HVR-H3 comprises SEQ ID NO:19.

9. The use of claim 8, wherein the loading dose is between about 400 mg and about 450 mg and the maintenance dose is between about 50 mg and about 350 mg.

10. The use of claim 9, wherein the loading dose is about 400 mg, or about 420 mg, or about 430 mg, or about 450 mg.

11. The use of claim 9, wherein the maintenance dose is about 50 mg, or about 100 mg, or about 150 mg, or about 200 mg, or about 300 mg, or about 350 mg.

12. The use of claim 9, wherein the loading dose and the maintenance dose are selected from the group consisting of:

(i) the loading dose is about 400 mg and the maintenance dose is about 50 mg, or about 100 mg, or about 150 mg, or about 200 mg, or about 300 mg, or about 350 mg;

(ii) the loading dose is about 420 mg and the maintenance dose is about 50 mg, or about 100 mg, or about 150 mg, or about 200 mg, or about 300 mg, or about 350 mg;

(iii) the loading dose is about 430 mg and the maintenance dose is about 50 mg, or about 100 mg, or about 150 mg, or about 200 mg, or about 300 mg, or about 350 mg;

(iv) the loading dose is about 450 mg and the maintenance dose is about 50 mg, or about 100 mg, or about 150 mg, or about 200 mg, or about 300 mg, or about 350 mg;

(v) the loading dose is about 400 mg, or about 420 mg, or about 430 mg, or about 450 mg and the maintenance dose is about 50 mg;

(vi) the loading dose is about 400 mg, or about 420 mg, or about 430 mg, or about 450 mg and the maintenance dose is about 100 mg;

(vii) the loading dose is about 400 mg, or about 420 mg, or about 430 mg, or about 450 mg and the maintenance dose is about 150 mg;

(viii) the loading dose is about 400 mg, or about 420 mg, or about 430 mg, or about 450 mg and the maintenance dose is about 200 mg;

(ix) the loading dose is about 400 mg, or about 420 mg, or about 430 mg, or about 450 mg and the maintenance dose is about 300 mg; and

(x) the loading dose is about 400 mg, or about 420 mg, or about 430 mg, or about 450 mg and the maintenance dose is about 350 mg.

13. The use of claim 10, wherein the loading dose is about 420 mg.

14. The use of claim 10, wherein the loading dose is about 450 mg.

15. The use of claim 13 or 14, wherein the maintenance dose is about 350 mg.

16. The use of claim 8, wherein the first maintenance dose is to be administered one day, or one week, or two weeks, or four weeks after the loading dose, or on the same day as the loading dose.

17. The use of claim 16, wherein the second and each subsequent maintenance dose is to be administered every two weeks, or every four weeks, or every eight weeks.

18. The use of claim 8, wherein the first maintenance dose is to be administered two weeks after the loading dose, the second maintenance dose is to be administered two weeks after the first maintenance dose, and each subsequent maintenance dose is to be administered every four weeks.

19. The use of claim 8, wherein the anti-beta7 antibody is to be administered for a period of two months, or three months, or six months, or 12 months, or 18 months, or 24 months, or for the lifetime of the patient.

20. The use of claim 8, wherein the patient is a human.

21. The use of claim 8, wherein the gastrointestinal inflammatory disorder is an inflammatory bowel disease, and wherein optionally the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

22. The use of claim 8, wherein the anti-beta7 antibody is selected from a chimeric antibody, a human antibody, and a humanized antibody.

23. The use of claim 22, wherein the anti-beta7 antibody is a humanized antibody.

24. The use according to any one of claims 1-23, wherein the anti-beta7 antibody is to be administered with at least one additional compound selected from 5- aminosalicylic acid (5-ASA), azathioprine (AZA), 6-mercaptopurine (6-MP), and methotrexate.

25. The use according to any one of claims 1-23, wherein the patient previously failed at least one biological agent, and wherein optionally the biological agent is selected from adalimumab, etanercept, infliximab, golimumab, certolizumab pegol, natalizumab, and vedolizumab.

26. The use according to any one of claims 1-23, wherein the anti-beta7 antibody to be administered with a self-inject device, and wherein optionally the self-inject device is selected from a prefilled syringe, microneedle device, autoinjector device and needle-free injection device.

27. Use of a monoclonal anti-beta7 antibody in the manufacture of a medicament for inducing remission in a patient suffering from ulcerative colitis, wherein the anti-beta7 antibody is to be administered subcutaneously at a flat dose of either about 100 mg or about 300 mg every four weeks, wherein the anti-beta7 antibody comprises three heavy chain hypervariable region (HVR-H1-H3) sequences and three light chain hypervariable region (HVR-L1-L3) sequences, wherein:

(i) HVR-L1 comprises SEQ ID NO:9;
(ii) HVR-L2 comprises SEQ ID NO:2;
(iii) HVR-L3 comprises SEQ ID NO:3;
(iv) HVR-H1 comprises SEQ ID NO:4;
(v) HVR-H2 comprises SEQ ID NO:5; and
(vi) HVR-H3 comprises SEQ ID NO: 19.

28. The use of claim 27, further comprising determining a Mayo Clinic Score and Mayo Clinic subscores, wherein the patient is determined to have an absolute Mayo Clinic Score < 2 and no

individual subscore >1, and wherein optionally remission is induced at least by week 10 following the first administration of etrolizumab.

29. Use of a monoclonal anti-beta7 antibody in the manufacture of a medicament for inducing sustained remission in a patient suffering from ulcerative colitis, wherein the anti-beta7 antibody is to be administered subcutaneously at a flat dose of either about 100 mg or about 300 mg every four weeks, wherein remission is retained for a period of 8 weeks following induction of remission, or a period of 30 weeks following induction of remission, or a period of 50 weeks following induction of remission, or a period of 54 weeks or more following induction of remission, wherein the anti-beta7 antibody comprises three heavy chain hypervariable region (HVR-H1-H3) sequences and three light chain hypervariable region (HVR-L1-L3) sequences, wherein:

(i) HVR-L1 comprises SEQ ID NO:9;
(ii) HVR-L2 comprises SEQ ID NO:2;
(iii) HVR-L3 comprises SEQ ID NO:3;
(iv) HVR-H1 comprises SEQ ID NO:4;
(v) HVR-H2 comprises SEQ ID NO:5; and
(vi) HVR-H3 comprises SEQ ID NO: 19.

30. The use of claim 29, wherein the remission is steroid-free remission, and wherein optionally the steroid-free remission is for 20 weeks following induction of remission, or for 24 weeks or longer following induction of remission.

~~WHAT IS CLAIMED IS:~~

1. Use of an integrin beta7 antagonist in the manufacture of a medicament for treating a gastrointestinal inflammatory disorder in a patient, wherein the integrin beta7 antagonist is to be administered subcutaneously.

2. The use of claim 1, wherein the integrin beta7 antagonist is a monoclonal anti-beta7 antibody,

wherein optionally the anti-beta7 antibody is to be administered at a dose of 0.5 mg/kg, or 1.5 mg/kg, or 3.0 mg/kg, or 4.0 mg/kg,

wherein optionally the anti-beta7 antibody is to be administered once every four weeks,

and wherein optionally the anti-beta7 antibody is to be administered for a period of two months, or three months, or six months, or 12 months, or 18 months, or 24 months, or for the lifetime of the patient.

3. The use of claim 1, wherein the patient is a human.

4. The use of claim 1, wherein the gastrointestinal inflammatory disorder is an inflammatory bowel disease, and

wherein optionally the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

5. The use of claim 2, wherein the anti-beta7 antibody is selected from a chimeric antibody, a human antibody, and a humanized antibody

6. The use of claim 5, wherein the anti-beta7 antibody is an antibody fragment.

7. The use of claim 5, wherein the anti-beta7 antibody comprises six hypervariable regions (HVRs), wherein:

(i) HVR-L1 comprises amino acid sequence A1-A11, wherein A1-A11 is RASESVDTYLH (SEQ ID NO:1); RASESVDSLLH (SEQ ID NO:7), RASESVDTLLH (SEQ ID NO:8), or RASESVDDLLH (SEQ ID NO:9) or a variant of SEQ ID NOs:1, 7, 8 or 9 (SEQ ID NO:26) wherein amino acid A2 is selected from the group consisting of A, G, S, T, and V and/or amino acid A3 is selected from the group consisting of S, G, I, K, N, P, Q, R, and T, and/or A4 is selected from the group consisting of E, V, Q, A, D, G, H, I, K, L, N, and R, and/or amino acid A5 is selected from the group consisting of S, Y, A, D, G, H, I, K, N, P, R, T, and V, and/or amino acid A6 is selected from the group consisting of V, R, I, A, G, K, L, M, and Q, and/or amino acid A7 is selected from the group consisting of D, V, S, A, E, G,

~~H, I, K, L, N, P, S, and T, and/or amino acid A8 is selected from the group consisting of D,~~ G, N, E, T, P and S, and/or amino acid A9 is selected from the group consisting of L, Y, I and M, and/or amino acid A10 is selected from the group consisting of L, A, I, M, and V and/or amino acid A11 is selected from the group consisting of H, Y, F, and S;

(ii) HVR-L2 comprises amino acid sequence B1-B8, wherein B1-B8 is KYASQSIS (SEQ ID NO:2), RYASQSIS (SEQ ID NO:20), or XaaYASQSIS (SEQ ID NO:21, where Xaa represents any amino acid) or a variant of SEQ ID NOs:2, 20 or 21 (SEQ ID NO:27) wherein amino acid B1 is selected from the group consisting of K, R, N, V, A, F, Q, H, P, I, L, Y and Xaa (where Xaa represents any amino acid), and/or amino acid B4 is selected from the group consisting of S and D, and/or amino acid B5 is selected from the group consisting of Q and S, and/or amino acid B6 is selected from the group consisting of S, D, L, and R, and/or amino acid B7 is selected from the group consisting of I, V, E, and K;

(iii) HVR-L3 comprises amino acid sequence C1-C9, wherein C1-C9 is QQGNSLPNT (SEQ ID NO:3) or a variant of SEQ ID NO:3 (SEQ ID NO:28) wherein amino acid C8 is selected from the group consisting of N, V, W, Y, R, S, T, A, F, H, I L, and M;

(iv) HVR-H1 comprises amino acid sequence D1-D10 wherein D1-D10 is GFFITNNYWG (SEQ ID NO:4);

(v) HVR-H2 comprises amino acid sequence E1-E17 wherein E1-E17 is GYISYSGSTSYNPSLKS (SEQ ID NO:5), or a variant of SEQ ID NO:5 (SEQ ID NO:29) wherein amino acid E2 is selected from the group consisting of Y, F, V, and D, and/or amino acid E6 is selected from the group consisting of S and G, and/or amino acid E10 is selected from the group consisting of S and Y, and/or amino acid E12 is selected from the group consisting of N, T, A, and D, and/or amino acid 13 is selected from the group consisting of P, H, D, and A, and/or amino acid E15 is selected from the group consisting of L and V, and/or amino acid E17 is selected from the group consisting of S and G; and

(vi) HVR-H3 comprises amino acid sequence F2-F11 wherein F2 -F11 is MTGSSGYFDF (SEQ ID NO:6) or RTGSSGYFDF (SEQ ID NO:19); or comprises amino acid sequence F1-F11, wherein F1-F11 is AMTGSSGYFDF (SEQ ID NO:16), ARTGSSGYFDF (SEQ ID NO:17), or AQTGSSGYFDF (SEQ ID NO:18), or a variant of SEQ ID NOs:6, 16, 17, 18, or 19 (SEQ ID NO:30) wherein amino acid F2 is R, M, A, E, G, Q, S, and/or amino acid F11 is selected from the group consisting of F and Y,

~~and wherein optionally the anti-beta7 antibody comprises three heavy chain hypervariable~~ region (HVR-H1-H3) sequences and three light chain hypervariable region (HVR-L1-L3) sequences, wherein:

(i) HVR-L1 comprises SEQ ID NO:7, SEQ ID NO:8 or SEQ ID NO:9;

(ii) HVR-L2 comprises SEQ ID NO:2;

(iii) HVR-L3 comprises SEQ ID NO:3;

(iv) HVR-H1 comprises SEQ ID NO:4;

(v) HVR-H2 comprises SEQ ID NO:5; and

(vi) HVR-H3 comprises SEQ ID NO:6 or SEQ ID NO:16 or SEQ ID NO:17 or SEQ ID NO:19.

8. Use of an integrin beta7 antagonist in the manufacture of a medicament for treating a gastrointestinal inflammatory disorder in a patient, wherein the integrin beta7 antagonist is to be administered subcutaneously at a flat dose.

9. The use of claim 8, wherein the integrin beta7 antagonist is a monoclonal anti-beta7 antibody,

wherein optionally the anti-beta7 antibody is to be administered at a flat dose between 50 mg and 450 mg,

wherein optionally the flat dose is selected from the group consisting of 50 mg,

100 mg,

150 mg,

200 mg,

300 mg,

350 mg,

400 mg,

420 mg, and

450 mg,

wherein optionally the anti-beta7 antibody is to be administered once every week, or once or every two weeks, or once every four weeks, or once every six weeks, or once every eight weeks,

and wherein optionally the anti-beta7 antibody is to be administered for a period of two months, or three months, or six months, or 12 months, or 18 months, or 24 months, or for the lifetime of the patient.

10. The use of claim 8, wherein the patient is a human.

~~11. The use of claim 8, wherein the gastrointestinal inflammatory disorder is an~~ inflammatory bowel disease,
and wherein optionally the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

12. The use of claim 9, wherein the anti-beta7 antibody is selected from a chimeric antibody, a human antibody, and a humanized antibody.

13. The use of claim 12, wherein the anti-beta7 antibody is an antibody fragment.

14. The use of claim 12, wherein the anti-beta7 antibody comprises six hypervariable regions (HVRs), wherein:

(i) HVR-L1 comprises amino acid sequence A1-A11, wherein A1-A11 is RASESVDTYLH (SEQ ID NO:1); RASESVDSLLH (SEQ ID NO:7), RASESVDTLLH (SEQ ID NO:8), or RASESVDDLLH (SEQ ID NO:9) or a variant of SEQ ID NOs:1, 7, 8 or 9 (SEQ ID NO:26) wherein amino acid A2 is selected from the group consisting of A, G, S, T, and V and/or amino acid A3 is selected from the group consisting of S, G, I, K, N, P, Q, R, and T, and/or A4 is selected from the group consisting of E, V, Q, A, D, G, H, I, K, L, N, and R, and/or amino acid A5 is selected from the group consisting of S, Y, A, D, G, H, I, K, N, P, R, T, and V, and/or amino acid A6 is selected from the group consisting of V, R, I, A, G, K, L, M, and Q, and/or amino acid A7 is selected from the group consisting of D, V, S, A, E, G, H, I, K, L, N, P, S, and T, and/or amino acid A8 is selected from the group consisting of D, G, N, E, T, P and S, and/or amino acid A9 is selected from the group consisting of L, Y, I and M, and/or amino acid A10 is selected from the group consisting of L, A, I, M, and V and/or amino acid A11 is selected from the group consisting of H, Y, F, and S;

(ii) HVR-L2 comprises amino acid sequence B1-B8, wherein B1-B8 is KYASQSIS (SEQ ID NO:2), RYASQSIS (SEQ ID NO:20), or XaaYASQSIS (SEQ ID NO:21, where Xaa represents any amino acid) or a variant of SEQ ID NOs:2, 20 or 21 (SEQ ID NO:27) wherein amino acid B1 is selected from the group consisting of K, R, N, V, A, F, Q, H, P, I, L, Y and Xaa (where Xaa represents any amino acid), and/or amino acid B4 is selected from the group consisting of S and D, and/or amino acid B5 is selected from the group consisting of Q and S, and/or amino acid B6 is selected from the group consisting of S, D, L, and R, and/or amino acid B7 is selected from the group consisting of I, V, E, and K;

(iii) HVR-L3 comprises amino acid sequence C1-C9, wherein C1-C9 is QQGNSLPNT (SEQ ID NO:3) or a variant of SEQ ID NO:3 (SEQ ID NO:28) wherein amino acid C8 is selected from the group consisting of N, V, W, Y, R, S, T, A, F, H, I L, and M;

(iv) HVR-H1 comprises amino acid sequence D1-D10 wherein D1-D10 is GFFITNNYWG (SEQ ID NO:4);

(v) HVR-H2 comprises amino acid sequence E1-E17 wherein E1-E17 is GYISYSGSTSYNPSLKS (SEQ ID NO:5), or a variant of SEQ ID NO:5 (SEQ ID NO:29)wherein amino acid E2 is selected from the group consisting of Y, F, V, and D, and/or amino acid E6 is selected from the group consisting of S and G, and/or amino acid E10 is selected from the group consisting of S and Y, and/or amino acid E12 is selected from the group consisting of N, T, A, and D, and/or amino acid 13 is selected from the group consisting of P, H, D, and A, and/or amino acid E15 is selected from the group consisting of L and V, and/or amino acid E17 is selected from the group consisting of S and G; and

(vi) HVR-H3 comprises amino acid sequence F2-F11 wherein F2 -F11 is MTGSSGYFDF (SEQ ID NO:6) or RTGSSGYFDF (SEQ ID NO:19); or comprises amino acid sequence F1-F11, wherein F1-F11 is AMTGSSGYFDF (SEQ ID NO:16), ARTGSSGYFDF (SEQ ID NO:17), or AQTGSSGYFDF (SEQ ID NO:18), or a variant of SEQ ID NOs:6, 16, 17, 18, or 19 (SEQ ID NO:30) wherein amino acid F2 is R, M, A, E, G, Q, S, and/or amino acid F11 is selected from the group consisting of F and Y,

wherein optionally the anti-beta7 antibody comprises three heavy chain hypervariable region (HVR-H1-H3) sequences and three light chain hypervariable region (HVR-L1-L3) sequences, wherein:

(i) HVR-L1 comprises SEQ ID NO:7, SEQ ID NO:8 or SEQ ID NO:9;

(ii) HVR-L2 comprises SEQ ID NO:2;

(iii) HVR-L3 comprises SEQ ID NO:3;

(iv) HVR-H1 comprises SEQ ID NO:4;

(v) HVR-H2 comprises SEQ ID NO:5; and

(vi) HVR-H3 comprises SEQ ID NO:6 or SEQ ID NO:16 or SEQ ID NO:17 or SEQ ID NO:19, and

wherein optionally the anti-beta7 antibody is to be administered at a flat dose of 100 mg or 300 mg every four weeks, wherein the patient suffers from ulcerative colitis, and wherein the patient experiences mucosal healing or a reduced rate of flare over time.

15. Use of an

integrin beta7 antagonist in the manufacture of a medicament for treating a gastrointestinal inflammatory disorder in a patient, wherein the patient is to be administered a first loading dose and at least one subsequent maintenance dose, wherein each of the loading dose and the at least one maintenance dose is to be administered subcutaneously at a flat dose.

16. The use of claim 15, wherein the integrin beta7 antagonist is a monoclonal anti-beta7 antibody.

17. The use of claim 16, wherein the loading dose is between 400 mg and 450 mg and the maintenance dose is between 50 mg and 350 mg,

18. The use of claim 17, wherein optionally the loading dose is 400 mg, or 420 mg, or 430 mg, or 450 mg; or

the maintenance dose is 50 mg, or 100 mg, or 150 mg, or 200 mg, or 300 mg, or 350 mg; or

the loading dose is 400 mg and the maintenance dose is 50 mg, or 100 mg, or 150 mg, or 200 mg, or 300 mg, or 350 mg; or

the loading dose is 420 mg and the maintenance dose is 50 mg, or 100 mg, or 150 mg, or 200 mg, or 300 mg, or 350 mg; or

the loading dose is 430 mg and the maintenance dose is 50 mg, or 100 mg, or 150 mg, or 200 mg, or 300 mg, or 350 mg; or

the loading dose is 450 mg and the maintenance dose is 50 mg, or 100 mg, or 150 mg, or 200 mg, or 300 mg, or 350 mg; or

the loading dose is 400 mg, or 420 mg, or 430 mg, or 450 mg and the maintenance dose is 50 mg; or

the loading dose is 400 mg, or 420 mg, or 430 mg, or 450 mg and the maintenance dose is 100 mg; or

the loading dose is 400 mg, or 420 mg, or 430 mg, or 450 mg and the maintenance dose is 150 mg; or

the loading dose is 400 mg, or 420 mg, or 430 mg, or 450 mg and the maintenance dose is 200 mg; or

the loading dose is 400 mg, or 420 mg, or 430 mg, or 450 mg and the maintenance dose is 350 mg.

19. The use of claim 17, wherein optionally the loading dose is 400 mg, or 420 mg, or 430 mg, or 450 mg and the maintenance dose is 300 mg.

20. The use of claim 19, wherein the loading dose is 420 mg.

21. The use of claim 19, wherein the loading dose is 450 mg.

22. The use of claim 17, wherein the first maintenance dose is to be administered one day, or one week, or two weeks, or four weeks after the loading dose, or on the same day as the loading dose.

23. The use of claim 22, wherein the second and each subsequent maintenance dose is to be administered every two weeks, or every four weeks, or every eight weeks.

24. The use of claim 17, wherein the first maintenance dose is to be administered two weeks after the loading dose, the second maintenance dose is to be administered two weeks after the first maintenance dose, and each subsequent maintenance dose is to be administered every four weeks.

25. The use of claim 17, wherein the anti-beta7 antibody is to be administered for a period of two months, or three months, or six months, or 12 months, or 18 months, or 24 months, or for the lifetime of the patient.

26. The use of claim 15, wherein the patient is a human.

27. The use of claim 15, wherein the gastrointestinal inflammatory disorder is an inflammatory bowel disease, and wherein optionally the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

28. The use of claim 16, wherein the anti-beta7 antibody is selected from a chimeric antibody, a human antibody, and a humanized antibody.

29. The use of claim 28, wherein the anti-beta7 antibody is an antibody fragment.

30. The use of claim 28, wherein the anti-beta7 antibody comprises six hypervariable regions (HVRs), wherein:

(i) HVR-L1 comprises amino acid sequence A1-A11, wherein A1-A11 is RASESVDTYLH (SEQ ID NO:1); RASESVDSLLH (SEQ ID NO:7), RASESVDTLLH (SEQ ID NO:8), or RASESVDDLLH (SEQ ID NO:9) or a variant of SEQ ID NOs:1, 7, 8 or 9 (SEQ ID NO:26) wherein amino acid A2 is selected from the group consisting of A, G, S, T, and V and/or amino acid A3 is selected from the group consisting of S, G, I, K, N, P, Q, R, and T, and/or A4 is selected from the group consisting of E, V, Q, A, D, G, H, I, K, L, N, and R, and/or amino acid A5 is selected from the group consisting of S, Y, A, D, G, H, I, K, N, P, R, T, and V, and/or amino acid A6 is selected from the group consisting of V, R, I, A, G, K, L, M, and Q, and/or amino acid A7 is selected from the group consisting of D, V, S, A, E, G, H, I, K, L, N, P, S, and T, and/or amino acid A8 is selected from the group consisting of D,

~~G, N, E, T, P and S, and/or amino acid A9 is selected from the group consisting of L, Y, I and~~ M, and/or amino acid A10 is selected from the group consisting of L, A, I, M, and V and/or amino acid A11 is selected from the group consisting of H, Y, F, and S;

(ii) HVR-L2 comprises amino acid sequence B1-B8, wherein B1-B8 is KYASQSIS (SEQ ID NO:2), RYASQSIS (SEQ ID NO:20), or XaaYASQSIS (SEQ ID NO:21, where Xaa represents any amino acid) or a variant of SEQ ID NOs:2, 20 or 21 (SEQ ID NO:27) wherein amino acid B1 is selected from the group consisting of K, R, N, V, A, F, Q, H, P, I, L, Y and Xaa (where Xaa represents any amino acid), and/or amino acid B4 is selected from the group consisting of S and D, and/or amino acid B5 is selected from the group consisting of Q and S, and/or amino acid B6 is selected from the group consisting of S, D, L, and R, and/or amino acid B7 is selected from the group consisting of I, V, E, and K;

(iii) HVR-L3 comprises amino acid sequence C1-C9, wherein C1-C9 is QQGNSLPNT (SEQ ID NO:3) or a variant of SEQ ID NO:3 (SEQ ID NO:28) wherein amino acid C8 is selected from the group consisting of N, V, W, Y, R, S, T, A, F, H, I L, and M;

(iv) HVR-H1 comprises amino acid sequence D1-D10 wherein D1-D10 is GFFITNNYWG (SEQ ID NO:4);

(v) HVR-H2 comprises amino acid sequence E1-E17 wherein E1-E17 is GYISYSGSTSYNPSLKS (SEQ ID NO:5), or a variant of SEQ ID NO:5 (SEQ ID NO:29) wherein amino acid E2 is selected from the group consisting of Y, F, V, and D, and/or amino acid E6 is selected from the group consisting of S and G, and/or amino acid E10 is selected from the group consisting of S and Y, and/or amino acid E12 is selected from the group consisting of N, T, A, and D, and/or amino acid 13 is selected from the group consisting of P, H, D, and A, and/or amino acid E15 is selected from the group consisting of L and V, and/or amino acid E17 is selected from the group consisting of S and G; and

(vi) HVR-H3 comprises amino acid sequence F2-F11 wherein F2 -F11 is MTGSSGYFDF (SEQ ID NO:6) or RTGSSGYFDF (SEQ ID NO:19); or comprises amino acid sequence F1-F11, wherein F1-F11 is AMTGSSGYFDF (SEQ ID NO:16), ARTGSSGYFDF (SEQ ID NO:17), or AQTGSSGYFDF (SEQ ID NO:18), or a variant of SEQ ID NOs:6, 16, 17, 18, or 19 (SEQ ID NO:30) wherein amino acid F2 is R, M, A, E, G, Q, S, and/or amino acid F11 is selected from the group consisting of F and Y, and

wherein optionally the anti-beta7 antibody comprises three heavy chain hypervariable region (HVR-H1-H3) sequences and three light chain hypervariable region (HVR-L1-L3) sequences, wherein:

(i) HVR-L1 comprises SEQ ID NO:7, SEQ ID NO:8 or SEQ ID NO:9;
(ii) HVR-L2 comprises SEQ ID NO:2;
(iii) HVR-L3 comprises SEQ ID NO:3;
(iv) HVR-H1 comprises SEQ ID NO:4;
(v) HVR-H2 comprises SEQ ID NO:5; and
(vi) HVR-H3 comprises SEQ ID NO:6 or SEQ ID NO:16 or SEQ ID NO:17 or SEQ ID NO:19.

31. The use according to any one of claims 1-21 or 24-30, wherein the integrin beta7 antagonist is to be administered with at least one additional compound selected from 5-aminosalicylic acid (5-ASA), azathioprine (AZA), 6-mercaptopurine (6-MP), and methotrexate.

32. The use according to any one of claims 1-21 or 24-30, wherein the patient previously failed at least one biological agent, and
wherein optionally the biological agent is selected from adalimumab, etanercept, infliximab, golimumab, certolizumab pegol, natalizumab, and vedolizumab.

33. The use of any one of claims 1-21 or 24-30, wherein the integrin beta7 antagonist is to be administered with a self-inject device, and
wherein optionally the self-inject device is selected from a prefilled syringe, microneedle device, autoinjector device and needle-free injection device.

34. An article of manufacture comprising a prefilled syringe comprising a liquid formulation of integrin beta7 antagonist, wherein the volume of the formulation is 2 ML and the amount of integrin beta7 antagonist is 150 mg.

35. An article of manufacture comprising a prefilled syringe comprising a liquid formulation of integrin beta7 antagonist, wherein the volume of the formulation is 1 ML and the amount of integrin beta7 antagonist is 180 mg.

36. The article of manufacture of claim 34 or 35, wherein the integrin beta7 antagonist is etrolizumab.

37. Use of etrolizumab in the manufacture of a medicament for inducing remission in a patient suffering from ulcerative colitis, wherein the etrolizumab is to be administered subcutaneously at a flat dose of either 100mg or 300 mg every four weeks.

~~38. The use of claim 37, further comprising determining a Mayo Clinic Score and~~ Mayo Clinic subscores, wherein the patient is determined to have an absolute Mayo Clinic Score ≤ 2 and no individual subscore >1, and

wherein optionally remission is induced at least by week 10 following the first administration of etrolizumab.

39. Use of etrolizumab in the manufacture of a medicament for inducing sustained remission in a patient suffering from ulcerative colitis, wherein the etrolizumab is to be administered subcutaneously at a flat dose of either 100mg or 300 mg every four weeks, wherein remission is retained for a period of 8 weeks following induction of remission, or a period of 30 weeks following induction of remission, or a period of 50 weeks following induction of remission, or a period of 54 weeks or more following induction of remission.

40. The use of claim 39, wherein the remission is steroid-free remission,

and wherein optionally the steroid-free remission is for 20 weeks following induction of remission, or for 24 weeks or longer following induction of remission.